Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01396382 · ClinicalTrials.gov registry record · Phase 2
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT01396382 is a Phase 2 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 97 participants.
The verdict
NCT01396382, a Phase 2 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET scan is a new generation of scans that might have improved sensitivity and resolution specifically for neuroendocrine tumors. The investigators will scan people with this cancer and compare it to other conventional imaging methods to see if it improves patient care.
Interventions
- RADIATION 68Ga-DOTATATE PET scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01396382
The ClinicalTrials.gov registry entry for NCT01396382 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 68Ga-DOTATATE PET scan is the first listed.
NCT01396382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01396382 about?
NCT01396382 is a clinical study titled "68Ga-DOTATATE PET Scan in Neuroendocrine Cancer". Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET scan is a new generation of scans that might have improved sensitivity and resolution specifically for neuroendocrine tumors. The investigators will scan people with this cancer and compar...
What is the current status of trial NCT01396382?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2010-03. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01396382?
The interventions under investigation include: 68Ga-DOTATATE PET scan (RADIATION).
Who is sponsoring clinical trial NCT01396382?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.